Table 3.
Question number with a significant factor association to the answers to the structured interview.
| Question | Factor | Level | N (row %) | p-value | ||||
|---|---|---|---|---|---|---|---|---|
| N | Not at all/A little | Moderately | Quite a bit/Extremely | missing | ||||
| Q1 | Gender | Female | 69 | 30 (45.5) | 17 (25.8) | 19 (28.8) | 3 (4.4) | |
| Male | 87 | 56 (66.7) | 16 (19.1) | 12 (14.3) | 3 (4.4) | 0.02 | ||
| Comorbidity | No | 42 | 20 (47.6) | 14 (33.3) | 4 (9.5) | 4 (9.5) | ||
| Yes | 114 | 66 (57.9) | 19 (16.7) | 27 (23.7) | 2 (1.8) | 0.006 | ||
| Previous surgery/pulmonary RT | No | 83 | 52 (62.7) | 17 (20.5) | 9 (10.8) | 5 (6.0) | ||
| Yes | 73 | 34 (46.6) | 16 (21.9) | 22 (30.1) | 1 (1.4) | 0.01 | ||
| Therapya | CT,CT+IO,CT+RT | 48 | 30 (62.5) | 12 (25.0) | 6 (12.5) | 0 | ||
| IO | 35 | 22 (62.9) | 2 (5.7) | 9 (25.7) | 2 (5.7) | 0.02 | ||
| Q2 | Gender | Female | 69 | 31 (47.0) | 22 (33.3) | 13 (19.7) | 3 (4.4) | |
| Male | 87 | 63 (74.1) | 13 (15.3) | 9 (10.6) | 2 (2.3) | 0.003 | ||
| Comorbidity | No | 42 | 25 (59.5) | 11 (26.2) | 2 (4.8) | 4 (9.5) | ||
| Yes | 114 | 69 (60.5) | 24 (21.1) | 20 (17.5) | 1 (0.9) | 0.01 | ||
| Q3 | Therapy | No therapy | 18 | 5 (29.4) | 8 (47.1) | 3 (17.7) | 1 (5.9) | |
| Intravenousb | 83 | 48 (57.1) | 22 (26.2) | 10 (12.1) | 3 (3.6) | |||
| TKI | 55 | 17 (30.9) | 15 (27.3) | 18 (32.7) | 5 (9.1) | 0.009c | ||
| Months from cancer diagnosis | ≤3 | 28 | 11 (39.3) | 10 (35.7) | 2 (7.1) | 5 (17.9) | ||
| (3,12] | 32 | 19 (59.4) | 9 (28.1) | 3 (9.4) | 1 (3.1) | |||
| >12 | 96 | 40 (41.7) | 26 (27.1) | 27 (28.1) | 3 (3.1) | 0.01 | ||
| Q4 | Months from cancer diagnosis | ≤3 | 28 | 13 (46.4) | 8 (28.6) | 2 (7.1) | 5 (17.9) | |
| (3,12] | 32 | 24 (75.0) | 5 (15.6) | 2 (6.3) | 1 (3.1) | |||
| >12 | 96 | 55 (57.3) | 24 (25.0) | 15 (15.6) | 2 (2.1) | 0.03 | ||
| Q8 | Therapy | Intravenousc | 83 | 34 (70.8) | 7 (14.6) | 7 (14.6) | 0 | |
| TKI | 55 | 25 (45.5) | 13 (23.6) | 13 (23.6) | 4 (7.3) | 0.04 | ||
aN= 83 patients receiving intravenous treatment subgroup; bIntravenous: CT,CT+IO,CT+RT,IO; cIntravenous vs. TKI comparison (excluding No therapy level), p = 0.003;
CT, chemotherapy; IO, immunotherapy; RT, radiotherapy; TKI, tyrosine kinase inhibitors.